Zafari Zafar, Sin Don D, Postma Dirkje S, Löfdahl Claes-Göran, Vonk Judith, Bryan Stirling, Lam Stephen, Tammemagi C Martin, Khakban Rahman, Man S F Paul, Tashkin Donald, Wise Robert A, Connett John E, McManus Bruce, Ng Raymond, Hollander Zsuszanna, Sadatsafavi Mohsen
Centre for Clinical Epidemiology and Evaluation (Zafari, Bryan, Sadatsafavi), Vancouver Coastal Health Research Institute, University of British Columbia; Centre for Heart and Lung Innovation (Sin, Man, McManus, Hollander), St. Paul's Hospital; Institute for Heart and Lung Health (Sin, Man, McManus, Hollander, Sadatsafavi), University of British Columbia; Division of Respiratory Medicine (Sin, Lam, Man, Sadatsafavi), Department of Medicine, University of British Columbia, Vancouver, BC; University Medical Center Groningen (Postma, Vonk), Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, Groningen; University Medical Center Groningen (Postma), Department of Pulmonary Diseases, University of Groningen, Groningen, the Netherlands; Department of Respiratory Medicine and Allergology (Löfdahl), Lund University, Lund, Sweden; Department of Epidemiology (Vonk), University of Groningen, University Medical Center Groningen, the Netherlands; School of Population and Public Health (Bryan), University of British Columbia, Vancouver, BC; Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences (Khakban), University of British Columbia, Vancouver, BC; David Geffen School of Medicine at UCLA (Tashkin), Los Angeles, Calif.; Johns Hopkins University School of Medicine (Wise), Baltimore, Md.; University of Minnesota School of Public Health (Connett), Minneapolis, Minn.; PROOF Centre for Excellence (McManus, Ng, Hollander), Vancouver, BC; Department of Community Health Sciences (Tammemagi), Brock University, St. Catharines, Ont.
CMAJ. 2016 Oct 4;188(14):1004-1011. doi: 10.1503/cmaj.151483. Epub 2016 Aug 2.
The rate of lung-function decline in chronic obstructive pulmonary disease (COPD) varies substantially among individuals. We sought to develop and validate an individualized prediction model for forced expiratory volume at 1 second (FEV) in current smokers with mild-to-moderate COPD.
Using data from a large long-term clinical trial (the Lung Health Study), we derived mixed-effects regression models to predict future FEV values over 11 years according to clinical traits. We modelled heterogeneity by allowing regression coefficients to vary across individuals. Two independent cohorts with COPD were used for validating the equations.
We used data from 5594 patients (mean age 48.4 yr, 63% men, mean baseline FEV 2.75 L) to create the individualized prediction equations. There was significant between-individual variability in the rate of FEV decline, with the interval for the annual rate of decline that contained 95% of individuals being -124 to -15 mL/yr for smokers and -83 to 15 mL/yr for sustained quitters. Clinical variables in the final model explained 88% of variation around follow-up FEV. The C statistic for predicting severity grades was 0.90. Prediction equations performed robustly in the 2 external data sets.
A substantial part of individual variation in FEV decline can be explained by easily measured clinical variables. The model developed in this work can be used for prediction of future lung health in patients with mild-to-moderate COPD.
Lung Health Study - ClinicalTrials.gov, no. NCT00000568; Pan-Canadian Early Detection of Lung Cancer Study - ClinicalTrials.gov, no. NCT00751660.
慢性阻塞性肺疾病(COPD)患者的肺功能下降速率个体差异很大。我们试图开发并验证一个针对轻度至中度COPD现吸烟者1秒用力呼气量(FEV)的个体化预测模型。
利用一项大型长期临床试验(肺部健康研究)的数据,我们推导了混合效应回归模型,根据临床特征预测11年内的未来FEV值。我们通过允许回归系数在个体间变化来模拟异质性。使用两个独立的COPD队列来验证这些方程。
我们使用了5594例患者的数据(平均年龄48.4岁,63%为男性,平均基线FEV为2.75 L)来创建个体化预测方程。FEV下降速率存在显著的个体间差异,吸烟者年下降速率的95%个体区间为-124至-15 mL/年,持续戒烟者为-83至15 mL/年。最终模型中的临床变量解释了随访FEV周围88%的变异。预测严重程度等级的C统计量为0.90。预测方程在2个外部数据集中表现稳健。
FEV下降的个体差异很大一部分可以通过易于测量的临床变量来解释。本研究中开发的模型可用于预测轻度至中度COPD患者未来的肺部健康状况。
肺部健康研究 - ClinicalTrials.gov,编号NCT00000568;泛加拿大肺癌早期检测研究 - ClinicalTrials.gov,编号NCT00751660。